{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:03:34Z","timestamp":1776405814268,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"\u201cFond pour la Recherche Val d\u2019Aurelle\u201d"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10549-019-05349-y","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T13:45:40Z","timestamp":1562852740000},"page":"659-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Lopez-Crapez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Chaltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Durigova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Lacaze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Pouderoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Romieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Roch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"issue":"2","key":"5349_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/era.12.173","volume":"13","author":"A Provenzano","year":"2013","unstructured":"Provenzano A, Kurian S, Abraham J (2013) Overcoming endocrine resistance in breast cancer: role of the PI3\u00a0K and the mTOR pathways. Expert Rev Anticancer Ther 13(2):143\u2013147. \n                    https:\/\/doi.org\/10.1586\/era.12.173","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 2","key":"5349_CR2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.breast.2013.08.001","volume":"22","author":"X Fu","year":"2013","unstructured":"Fu X, Osborne CK, Schiff R (2013) Biology and therapeutic potential of PI3\u00a0K signaling in ER+\/HER2-negative breast cancer. Breast 22(Suppl 2):S12\u201318. \n                    https:\/\/doi.org\/10.1016\/j.breast.2013.08.001","journal-title":"Breast"},{"issue":"3","key":"5349_CR3","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr3683","volume":"16","author":"E Lopez-Knowles","year":"2014","unstructured":"Lopez-Knowles E, Segal CV, Gao Q, Garcia-Murillas I, Turner NC, Smith I, Martin LA, Dowsett M (2014) Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res 16(3):R68. \n                    https:\/\/doi.org\/10.1186\/bcr3683","journal-title":"Breast Cancer Res"},{"issue":"1","key":"5349_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-013-2529-7","volume":"139","author":"DE Ramirez-Ardila","year":"2013","unstructured":"Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP (2013) Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139(1):39\u201349. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2529-7","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5349_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/jclinpath-2015-202885","volume":"68","author":"K Lai","year":"2015","unstructured":"Lai K, Killingsworth MC, Lee CS (2015) Gene of the month: PIK3CA. J Clin Pathol 68(4):253\u2013257. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2015-202885","journal-title":"J Clin Pathol"},{"issue":"4","key":"5349_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","volume":"25","author":"K Araki","year":"2018","unstructured":"Araki K, Miyoshi Y (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3\u00a0K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 25(4):392\u2013401. \n                    https:\/\/doi.org\/10.1007\/s12282-017-0812-x","journal-title":"Breast Cancer"},{"issue":"12","key":"5349_CR7","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","volume":"18","author":"MJ Higgins","year":"2012","unstructured":"Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH (2012) Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 18(12):3462\u20133469. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2696","journal-title":"Clin Cancer Res"},{"issue":"7757","key":"5349_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, Andre F (2019) Genomic characterization of metastatic breast cancers. Nature 569(7757):560\u2013564. \n                    https:\/\/doi.org\/10.1038\/s41586-019-1056-z","journal-title":"Nature"},{"issue":"11","key":"5349_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/jcp.2007.047720","volume":"61","author":"G Bussolati","year":"2008","unstructured":"Bussolati G, Leonardo E (2008) Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61(11):1184\u20131192. \n                    https:\/\/doi.org\/10.1136\/jcp.2007.047720","journal-title":"J Clin Pathol"},{"issue":"4","key":"5349_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.anndiagpath.2013.02.001","volume":"17","author":"VM Singh","year":"2013","unstructured":"Singh VM, Salunga RC, Huang VJ, Tran Y, Erlander M, Plumlee P, Peterson MR (2013) Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 17(4):322\u2013326. \n                    https:\/\/doi.org\/10.1016\/j.anndiagpath.2013.02.001","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"5349_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JTO.0b013e3182307f98","volume":"7","author":"K Goto","year":"2012","unstructured":"Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M (2012) Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin\/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7(1):115\u2013121. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e3182307f98","journal-title":"J Thorac Oncol"},{"key":"5349_CR12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3377","author":"TW Kim","year":"2018","unstructured":"Kim TW, Peeters M, Thomas AL, Gibbs P, Hool K, Zhang J, Ang A, Bach BA, Price T (2018) Impact of emergent circulating tumor DNA RAS mutation in panitumumab-treated chemoresistant metastatic colorectal cancer. Clin Cancer Res. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3377","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5349_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10549-010-0747-9","volume":"120","author":"RE Board","year":"2010","unstructured":"Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C (2010) Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 120(2):461\u2013467. \n                    https:\/\/doi.org\/10.1007\/s10549-010-0747-9","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"5349_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(7):904\u2013916. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30376-5","journal-title":"Lancet Oncol"},{"issue":"5","key":"5349_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabieres","year":"2016","unstructured":"Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479\u2013491. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1483","journal-title":"Cancer Discov"},{"issue":"2","key":"5349_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-006-9253-5","volume":"100","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100(2):237\u2013238. \n                    https:\/\/doi.org\/10.1007\/s10549-006-9253-5","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"5349_CR17","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ejca.2005.03.032","volume":"41","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41(12):1690\u20131696. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2005.03.032","journal-title":"Eur J Cancer"},{"issue":"4","key":"5349_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jmoldx.2015.02.004","volume":"17","author":"PJ Lamy","year":"2015","unstructured":"Lamy PJ, Castan F, Lozano N, Montelion C, Audran P, Bibeau F, Roques S, Montels F, Laberenne AC (2015) Next-generation genotyping by digital PCR to detect and quantify the BRAF V600E Mutation in melanoma biopsies. J Mol Diagn 17(4):366\u2013373. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2015.02.004","journal-title":"J Mol Diagn"},{"key":"5349_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ebiom.2018.05.015","volume":"32","author":"ZY Hu","year":"2018","unstructured":"Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Xiao M, Tang Y, He Q, Chang L, Xia X, Yi X, Liao Q, Ouyang Q (2018) Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance. EBioMedicine 32:111\u2013118. \n                    https:\/\/doi.org\/10.1016\/j.ebiom.2018.05.015","journal-title":"EBioMedicine"},{"issue":"10","key":"5349_CR20","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdu288","volume":"25","author":"F Rothe","year":"2014","unstructured":"Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25(10):1959\u20131965. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu288","journal-title":"Ann Oncol"},{"key":"5349_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/OTT.S60115","volume":"7","author":"YR Liu","year":"2014","unstructured":"Liu YR, Jiang YZ, Zuo WJ, Yu KD, Shao ZM (2014) PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. OncoTargets Ther 7:543\u2013552. \n                    https:\/\/doi.org\/10.2147\/OTT.S60115","journal-title":"OncoTargets Ther"},{"issue":"7","key":"5349_CR22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O\u2019Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541\u20131547. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"issue":"20","key":"5349_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Papai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D, Group S-S, the S-SG (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"1","key":"5349_CR24","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC (2018) Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 9(1):896. \n                    https:\/\/doi.org\/10.1038\/s41467-018-03215-x","journal-title":"Nat Commun"},{"issue":"1","key":"5349_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA (2014) CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3\u00a0K inhibitors. Cancer Cell 26(1):136\u2013149. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2014.05.020","journal-title":"Cancer Cell"},{"issue":"8","key":"5349_CR26","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortes J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V (2016) Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76(8):2301\u20132313. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0728","journal-title":"Cancer Res"},{"issue":"40","key":"5349_CR27","doi-asserted-by":"publisher","first-page":"66020","DOI":"10.18632\/oncotarget.11791","volume":"7","author":"F Ma","year":"2016","unstructured":"Ma F, Zhu W, Guan Y, Yang L, Xia X, Chen S, Li Q, Guan X, Yi Z, Qian H, Yi X, Xu B (2016) ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget 7(40):66020\u201366031. \n                    https:\/\/doi.org\/10.18632\/oncotarget.11791","journal-title":"Oncotarget"},{"issue":"12","key":"5349_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48(12):1503\u20131510","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"5349_CR29","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1007\/s13277-016-4924-2","volume":"37","author":"E Dirican","year":"2016","unstructured":"Dirican E, Akkiprik M, Ozer A (2016) Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol 37(6):7033\u20137045. \n                    https:\/\/doi.org\/10.1007\/s13277-016-4924-2","journal-title":"Tumour Biol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05349-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05349-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05349-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:24:01Z","timestamp":1594337041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05349-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["5349"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05349-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the CPP (Ethics Committee) Sud-Ouest et Outre-Mer III and registered under the reference No. 2012\/25. This study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}